Rezq Bio

Rezq Bio is a small, early stage biotechnology company based in Pittsburgh, Pennsylvania. With a team of three employees, the company focuses on developing innovative therapies for chronic autoimmune diseases. Rezq Bio's primary focus is on finding a cure for Type 1 Diabetes (T1D) and other localized autoimmune conditions. Their lead asset is a Phase 1B/2A ready autologous dendritic cell therapy specifically designed to treat T1D. The company's antisense (ASO) technology platform has the potential to be applied to various other localized autoimmune conditions, including Colitis, Multiple Sclerosis, and Autoimmune Polyneuropathy. Rezq Bio's differentiation lies in its development of a novel autologous dendritic cell therapy for T1D. This therapy, along with their ASO technology platform, offers a potentially groundbreaking approach to treating these debilitating conditions. They have also successfully delivered microspheres loaded with ASOs as well as RA+TGF-B preclinically, demonstrating a promising off-the-shelf delivery mechanism. For more information about Rezq Bio and its groundbreaking research, visit their website at rezq.bio.